ஜர்னல் ஆஃப் ஹெமாட்டாலஜி & த்ரோம்போம்போலிக் நோய்கள்
திறந்த அணுகல்

சுருக்கம்

The 2006 2008 European Clinical, Molecular and Patholobiogical (2008 ECMP) Classification and the 2007 WHO Revised Criteria for Myeloproliferative Neoplasms

Jan J Michiels, Zwi Berneman, Wilfried Schroyens, Konnie Hebeda, King H Lam, Francisca Valster, Vincent Potter, Katrien Schelfout, Hendrik De Raeve

The classifications of Myeloproliferative Disorders (MPD) by the Polycythemia Vera Study Group (PVSG) and World Health Organization (WHO) used crude criteria for the diagnoses of Essential Thrombocythemia (ET), Polycythemia Vera (PV) and Primary Myelo Fibrosis (PMF). The PVSG and the 2007 WHO criteria for the diagnosis of ET and PVoverlook the very early prefibrotic stages of MPN. The 2008 European Clinical, Molecular and Pathological (2008 ECMP) criteria are sensitive for the detection of early stages of JAK2V617F trilinear Myelo Proliferative Neoplasms (MPN) and could delineate three stages JAK2V617F mutated ET: normocellular ET; ET with features of early PV (prodromal PV); and ET with Hypercellular Megakaryocytic Granulocytic Myeloproliferation (EMGM). The 2008 ECMP classification distinguishes six clinical PV stages that have important prognostic and therapeutic implications. Spontaneous EEC, low serum erythropoietin (EPO) levels and JAK2 mutations are highly specific for ET with PV features (prodromal PV), masked PV and classical PV. JAK2 wild type ET and MF have no blood and bone marrow features of PV.

The detection and quantitation of JAK2V617F mutation allele burden play a key-role in the diagnostic work-up and staging of ET, PV and MF patients. The JAK2V617F mutation allele burden in heterozygous mutated ET and in combined heterozygous-homozygous or homozygous mutated PV and EMGM is of major clinical and prognostic significance. Pre-treatment bone marrow histopathology is of huge importance to document and stage the broad spectrum JAK2 mutated and JAK wild type MPN. JAK2 wild type ET carrying the MPL515 mutation is a separate and distinct MPN entity of ET and MF without features of PV at diagnosis and during follow-up. JAK2 wild type hypercellular ET associated with Primary Megakaryocytic Granulocytic Myeloproliferation (PMGM) is the third MPN entity of elusive etiology. Myelofibrosis (MF) is not a primary MPN disease entity because Reticulin Fibrosis (RF) and Reticulin/Collagen Fibrosis (RCF) are a secondary response of polyclonal fibroblasts to cytokines released from the clonal granulocytic and megakaryocytic proliferative cells.